Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 13,610 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatoses Clear all

Conditions: Breast Neoplasms
Interventions: Prayer; Behavioral
Lead sponsor: Southwestern Regional Medical Center; Other
Eligibility: 21 Years to 80 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Atopic Dermatitis
Interventions: EVO756, Placebo control; Drug
Lead sponsor: Evommune, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 24
States / cities: Phoenix, Arizona • Fremont, California • Los Angeles, California + 21 more

Conditions: Melanoma, Child
Interventions: FLARE; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 8 Years to 110 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Melanoma
Interventions: STA-4783, Paclitaxel; Drug
Lead sponsor: Synta Pharmaceuticals Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 28
States / cities: Hot Springs, Arkansas • Little Rock, Arkansas • San Diego, California + 25 more

Conditions: Alopecia Areata
Interventions: SHR0302; Drug
Lead sponsor: Reistone Biopharma Company Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Northridge, California • Brandon, Florida • Indianapolis, Indiana + 4 more

Conditions: Vitiligo
Interventions: Ruxolitinib cream, Vehicle cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 26
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Rogers, Arkansas + 21 more

Conditions: Acne Vulgaris
Interventions: Omiganan (CLS001) Topical Gel, Vehicle Topical Gel; Drug
Lead sponsor: Maruho Co., Ltd.; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 29
States / cities: Mobile, Alabama • Phoenix, Arizona • Santa Ana, California + 26 more

Conditions: Breast Cancer
Interventions: computed tomography (CT scan), computed tomography (CT scan); Radiation · Device
Lead sponsor: University of Rochester; Other
Eligibility: 40 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Hypotrichosis
Interventions: Track A, Track B; Drug
Lead sponsor: ATS Clinical Research; Other
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Breast Cancer, Breast Cancer Surgery
Interventions: Positron Emission Mammography (PEM); Device
Lead sponsor: Swedish Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Atopic Dermatitis
Interventions: Placebo, Rilzabrutinib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 9
States / cities: Northridge, California • Colorado Springs, Colorado • Miami, Florida + 5 more

Conditions: Imipramine, Photodynamic Therapy, Actinic Keratosis
Interventions: Imipramine, Vehicle; Drug · Other
Lead sponsor: Wright State University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Fairborn, Ohio

Conditions: Wrinkle, Rosacea, Scarring
Interventions: Excel V™ Laser With Green Genesis; Device
Lead sponsor: Cutera Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Epidermolysis Bullosa (EB), Epidermolysis Bullosa Simplex, Dystrophic Epidermolysis Bullosa, Junctional Epidermolysis Bullosa
Interventions: Diacerein 1% Ointment; Drug
Lead sponsor: Castle Creek Pharmaceuticals, LLC; Industry
Eligibility: 4 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Palo Alto, California • Chicago, Illinois • Chapel Hill, North Carolina

Conditions: Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma in Situ
Interventions: Molecular Breast Imaging, Screening Mammography; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cutaneous Lupus Erythematosus
Interventions: vitamin D; Dietary Supplement
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Epidermolysis Bullosa Dystrophica
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Herpes Labialis
Interventions: valacyclovir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 18
States / cities: Anaheim, California • Carmichael, California • Fair Oaks, California + 14 more

Conditions: Pruritus, Prurigo Nodularis
Interventions: 5mg Serlopitant Tablets, Placebo Tablets; Drug
Lead sponsor: Vyne Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 49
States / cities: Birmingham, Alabama • Rogers, Arkansas • Fremont, California + 44 more

Conditions: Depression, Breast Cancer, Stress, Breast Cancer Non-invasive Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Cancer Metastatic Breast Cancer
Interventions: Videoconferencing support group; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Herpes Simplex
Interventions: Valaciclovir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 1 Month to 6 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 10
States / cities: Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 7 more

Conditions: Atopic Dermatitis
Interventions: A written Eczema Action Plan (EAP); Other
Lead sponsor: Dermatology & Aesthetics of Wicker Park; Other
Eligibility: Not listed
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Early-Stage Breast Carcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions: Celecoxib, Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Paclitaxel, Recombinant Interferon Alfa-2b, Rintatolimod; Drug · Biological
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC), Melanoma, Cervical Cancer, Multiple Myeloma, Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma (DLBCL), Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
Interventions: AB308, Zimberelimab; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 15
States / cities: Los Angeles, California • Jacksonville, Florida • Goshen, Indiana + 12 more

Search by objective public record fields.

Prayer as a Possible Adjuvant Treatment for Breast Cancer

Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

Family Lifestyle Actions and Risk Education Study

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

A Phase II Study in Patients With Alopecia Areata

A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo

A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne Vulgaris

Role of 3D Tomography in Breast Cancer

Safety and Efficacy of Bimatoprost 0.03% Solution for the Treatment of Thinning Eyebrows

Pre-Surgery Positron Emission Mammography in Patients With Newly Diagnosed Breast Cancer

Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis

The Effect of Topical Imipramine on Pain and Effectiveness of Topical Photodynamic Therapy

Evaluation of Cutera Excel V™ Laser With Green Genesis and Micro-Lens Array (MLA)Attachment

To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)

Molecular Breast Imaging in Women With Atypia and LCIS

Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus

Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa

VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

Expanding Rural Access: Distance Delivery of Support Groups (Main Study)

A Safety And Tolerability Study Of Valaciclovir Oral Suspension In Infants And Children

Eczema Action Plan Improves Patient and Caregiver Understanding and Perception of Atopic Dermatitis Management

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies